Healthcare Industry News:  Edwards Lifesciences 

Devices Cardiology

 News Release - September 8, 2009

First Human Cases Performed With Edwards Lifesciences' New Transapical Heart Valve System

LEIPZIG, GERMANY - (HSMN NewsFeed) - Edwards Lifesciences Corporation (NYSE:EW ), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.

The procedures conducted at the University of Leipzig Heart Centre last week were the first in the PREVAIL TA study, a European clinical trial for the Edwards SAPIEN XT valve and Ascendra 2 system. This system enables valve delivery via a small incision between the ribs.

"Transapical valve replacement can now be achieved in fewer procedural steps as a result of the redesigned delivery system. The enhancements to the Ascendra 2 system make performing the transapical procedure easier and faster, which should result in broader surgeon and patient access to this approach," said Professor Thomas Walther, M.D., Ph.D., who performed the first implants with the new Ascendra 2 delivery system. Prof. Walther is professor of cardiac surgery and vice chairman at the University of Leipzig Heart Centre, Germany, and provides consulting services to Edwards Lifesciences as an educator and trainer for Edwards SAPIEN transcatheter valve procedures.

The system's benefits are achieved through a smaller introducer catheter and a more intuitive handle. The Ascendra 2 system has also been optimized specifically for the Edwards SAPIEN XT valve, which features a new leaflet shape patterned after Edwards' most durable surgical valves and a cobalt chromium balloon-expandable frame.

"The Ascendra 2 system is the result of direct surgeon feedback and close clinical partnership that has resulted in meaningful refinements to the system and procedure. We are proud to lead the advancement of this life-saving technology for high-risk patients with aortic stenosis," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement. Working with physicians, Edwards developed the first transapical transcatheter valve delivery system in 2005.

Edwards is the only company to have both transfemoral and transapical transcatheter valve delivery systems commercially available in Europe. The Edwards SAPIEN valve was approved for sale in Europe in late 2007, and has been used in the treatment of thousands of high-risk patients and evaluated as part of nine rigorous scientific studies.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

Ascendra 2, Edwards and Edwards SAPIEN XT are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Ascendra, Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Source: Edwards Lifesciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.